Tumor control in both Nkg7+/+ and Nkg7-/- mice was confirmed to be CD8+ T cell-mediated, as in vivo administration of CD8 depleting antibodies led to rapid tumor outgrowth in all mice (Figures 1E, F). In contrast to findings of a recent study, in which tumor growth in Nkg7-/- mice was compared to wild-type C57BL/6J mice (21), our results, generated using littermate controls, suggested that NKG7 is not required for effective anti-tumor CD8+ T cell immunity against MC38-OVA tumors in vivo. This evidence concerns the gene CD8A and neoplasm.